RNA medicines, particularly messenger RNA (mRNA), have illustrated how the combination of engineering and biology can reshape what is possible in human health. mRNA is a naturally occurring molecule that cells use to carry genetic instructions from DNA to the ribosome, where proteins are synthesized. In therapeutic applications, synthetic mRNA follows the same principle: once delivered into cells, it provides a temporary blueprint for producing a specific protein that can perform such functions as trigger an immune response, or replace a missing protein, or modulate cellular activity.
Attention due to the pandemic
Although mRNA entered public awareness during the COVID‑19 pandemic, the foundational science spans more than 60 years. The COVID‑19 vaccines demonstrated the full maturation of this technology: highly effective immunizations can be developed, manufactured, and deployed at unprecedented speed, with Moderna’s roughly 94 percent efficacy underscoring how far the field has advanced.
For comparison, the flu vaccine typically achieves approximately 40–50 percent efficacy. At the same time, key challenges remain, including extending the durability of protection, improving tolerability, and expanding delivery beyond the traditional intramuscular route to more patient convenient application routes like inhalation.
Looking ahead, the potential of RNA extends far beyond infectious diseases. Personalized cancer vaccines are already producing encouraging clinical results and are likely to become increasingly central to oncology care. In addition, nucleic acid delivery opens the door to areas such as protein replacement, gene editing, and cell‑specific modulation, provided we can reach the correct cells reliably and consistently. Achieving tissue‑ and cell‑targeted delivery remains one of the central bottlenecks in the field and, at the same time, one of its greatest opportunities.
Lipid nanoparticles have been essential for RNA therapeutics, providing stability and facilitating cellular uptake. Yet no single formulation can serve every therapeutic need. The ideal delivery system depends on cell type, tissue architecture, and disease biology. This is why combining rational design with high‑throughput experimental screening is essential, and why the integration of machine learning and other AI‑guided approaches is accelerating progress. These tools can now propose lipid combinations and formulation parameters that may offer faster routes toward extrahepatic and cell‑specific delivery, while also helping establish emerging design principles that improve safety and tolerability.
Equally important is recognizing that what we deliver must be matched by how we deliver it. Microneedle systems offer one minimally invasive way of administering RNA, with the promise of enabling more consistent vaccination and greater global reach.
In parallel, mucosal delivery is advancing rapidly, supported by material‑based strategies aimed at provoking strong immune responses directly at respiratory surfaces. Both approaches represent meaningful steps toward broadening access, improving patient experience, and aligning delivery with the natural biology of infection.
Improvements for Oncology and rare Diseases
As RNA platforms mature, progress is likely to unfold across several domains at once. Oncology will continue to benefit from more refined personalized vaccines and therapeutic combinations. Genetic and rare diseases will see improvements through targeted RNA and gene‑editing strategies that expand beyond the liver. Respiratory pathogens may increasingly be addressed through intranasal or pulmonary formulations that establish strong mucosal immunity. Immune and inflammatory disorders could benefit from RNA medicines capable of directing therapeutic signals to specific cell types.
Realizing this vision will require continued engineering innovation. Delivery systems must become more tunable so that RNA reaches the intended cells with sufficient potency and durability while avoiding adverse drug reactions. Safety profiles must continue to improve, even as existing mRNA vaccines already compare favorably with many traditional vaccines. Manufacturing and stability will play an equally important role: robust, scalable processes and formulations that maintain integrity at room temperature or in dry‑powder formats will be essential for global access. Finally, the field will continue to expand beyond LNPs alone. Polymers, hybrid systems, and device‑based solutions such as microneedles will complement, rather than replace, lipid nanoparticles, creating a broader toolkit that can be matched to diverse biological problems.
The Importance of the “Bump Effect”
None of this progress occurs in isolation. The Boston–Cambridge ecosystem, anchored by leading research universities, world class hospitals, and a dense network of entrepreneurs and investors, has been instrumental in accelerating the translation of fundamental discoveries into approved medicines. The “bump effect” of Kendall Square, where proximity promotes unexpected encounters, idea exchange, and the rapid formation of new teams and companies, remains a defining engine of innovation. A culture that embraces academic entrepreneurship continues to help breakthrough concepts transition from the lab to the clinic at remarkable speed.
If there is one message that captures the state of the field, it is that delivery remains both the critical step and the defining opportunity. As we invent better nanoparticles, smarter materials, and new administration routes, and as ecosystems like Boston–Cambridge continue to catalyze progress, RNA therapeutics can move from proofs of concept to widely used treatments across infectious disease, oncology, and many other areas of medicine.
ELEMENTS-Newsletter
Get exciting insights into Evonik’s research and its societal relevance—delivered conveniently by email.